Key Highlights
- LLY shares are trading at $1,154.85 in pre-market activity, up 1.50% from Monday's close of $1,137.75.
- Berenberg upgraded the stock to Buy from Hold and raised its price target to $1,400 from $1,220.
- The upgrade cites the market underestimating the value of Lilly's aggressive pipeline expansion, funded by roughly $60 billion in more than 25 Business development deals this year.
- Recent deals include the AtaiBeckley acquisition, adding a neurology and psychedelic asset, and the Centessa deal, adding narcolepsy candidate cimetorexant.
- Lilly holds more than 30% share of new starts in the oral obesity treatment market as it widens its lead over rival Novo Nordisk.
Berenberg Upgrade Cites Underappreciated Pipeline Value
Eli Lilly (NYSE:LLY) shares rose in pre-market trading Tuesday after Berenberg upgraded the stock to Buy from Hold and lifted its price target to $1,400 from $1,220. The research firm's upgrade argues that the market is underestimating the value of Lilly's aggressive pipeline expansion, which has been funded by the company's dominant diabetes and obesity drug franchise.
Berenberg's note highlighted that Lilly has deployed roughly $60 billion across more than 25 business development deals this year alone, positioning the company for growth well beyond its current GLP-1 franchise.
Recent Deals Widen the Pipeline Beyond GLP-1
Among the deals cited, the AtaiBeckley Acquisition adds a neurology and psychedelic asset designated BPL-003, while the Centessa transaction adds narcolepsy candidate cimetorexant, both diversifying Lilly's pipeline into therapeutic areas outside its core metabolic disease business. The upgrade comes as Lilly continues to widen its lead over rival Novo Nordisk, which recently rebranded itself as 'Novo' in an effort to close the obesity-market gap, with Lilly separately reported to now hold more than 30% share of new starts in the oral obesity treatment market.
Scale and Competitive Position
Eli Lilly's market Capitalization exceeds $1.1 trillion, with a forward price-to-earnings ratio of 27.84 and a trailing multiple of 38.18. Shares have traded within a 52-week range of $712.05 to $1,292.65 and carry a Dividend Yield of 0.59%. The company's portfolio spans diabetes treatments including Trulicity, Jardiance, Humalog, and Basaglar, oncology drugs such as Verzenio, and immunology therapies including Taltz and Omvoh.
Outlook Hinges on Converting Deals Into Approved Therapies
Berenberg's more bullish stance rests on Lilly successfully converting its rapid pace of licensing and acquisition activity into approved, commercially meaningful therapies over the coming years, rather than solely on continued GLP-1 momentum. Progress on the newly acquired neurology and narcolepsy assets, alongside continued execution in the obesity market, will likely be the key markers of whether the market comes around to Berenberg's higher valuation.






Please wait processing your request...